Anthony C Faber

Anthony C Faber

UNVERIFIED PROFILE

Are you Anthony C Faber?   Register this Author

Register author
Anthony C Faber

Anthony C Faber

Publications by authors named "Anthony C Faber"

Are you Anthony C Faber?   Register this Author

47Publications

1407Reads

32Profile Views

Investigating New Mechanisms of Acquired Resistance to Targeted Therapies: If You Hit Them Harder, Do They Get Up Differently?

Cancer Res 2020 Jan;80(1):25-26

Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Richmond, Virginia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-19-3405DOI Listing
January 2020

Respecting your elders: osimertinib demonstrates preferential activity in elderly patients with T790M positive non-small cell lung cancers.

J Thorac Dis 2019 Sep;11(Suppl 15):S1844-S1846

Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Richmond, VA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2019.08.122DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783766PMC
September 2019

Paragangliomas in Carney-Stratakis Syndrome.

Horm Metab Res 2019 Jul 7;51(7):437-442. Epub 2019 Jun 7.

VCU Massey Cancer Center - Hematology Oncology, Richmond, Virginia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-0918-8340DOI Listing
July 2019

Epithelial-to-mesenchymal transition and drug resistance: transitioning away from death.

J Thorac Dis 2019 Jun;11(6):E82-E85

Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Richmond, VA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2019.06.11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626797PMC
June 2019

OVOL2 in metastasis prevention in NPC.

Theranostics 2018 8;8(8):2242-2244. Epub 2018 Mar 8.

Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Richmond, VA 23298.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/thno.25181DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928884PMC
February 2019

BCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer.

Oncoscience 2018 Jul 14;5(7-8):218-219. Epub 2018 Aug 14.

Anthony Faber: Philips Institute for Oral Health Research, Virginia Commonwealth University School of Dentistry and Massey Cancer Center, Richmond, VA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncoscience.455DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142900PMC
July 2018

One gene to rule them all…and in the darkness bind them.

Mol Cell Oncol 2018 11;5(4):e1465881. Epub 2018 Jul 11.

Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Department of Oral and Craniofacial Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/23723556.2018.1465881DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149778PMC
July 2018

Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.

Oncogene 2018 03 19;37(13):1775-1787. Epub 2018 Jan 19.

Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Ishikawa, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-017-0035-9DOI Listing
March 2018

Coamplification of protects -amplified breast cancers from targeted therapy.

Proc Natl Acad Sci U S A 2018 03 23;115(11):E2594-E2603. Epub 2018 Feb 23.

Department of Oral and Craniofacial Molecular Biology, Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1717820115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856537PMC
March 2018

Classification of gastrointestinal stromal tumor syndromes.

Endocr Relat Cancer 2018 02 23;25(2):R49-R58. Epub 2017 Nov 23.

Massey Cancer CenterVCU School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-17-0329DOI Listing
February 2018

Gastrointestinal Stromal Tumors: The GIST of Precision Medicine.

Trends Cancer 2018 01 23;4(1):74-91. Epub 2017 Dec 23.

VCU Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trecan.2017.11.006DOI Listing
January 2018

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics.

Cancer Discov 2015 May 20;5(5):475-87. Epub 2015 Apr 20.

Virginia Commonwealth University Philips Institute for Oral Health Research, School of Dentistry and Massey Cancer Center, Richmond, Virginia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-15-0011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727530PMC
May 2015

Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations.

J Thorac Oncol 2015 Jan;10(1):59-66

*Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan; †Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Aichi, Japan; ‡Center for Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan; §Thoracic Surgery, Aichi Cancer Center Hospital, Aichi, Japan; ‖Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan; ¶VCU Philips Institute for Oral Health Research, School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA; #Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Aichi, Japan; **Department of Surgery, Division of Thoracic Surgery, Kinki University Faculty of Medicine, Osaka-Sayama, Japan; and ††Department of Preventive Medicine, Kyushu University Faculty of Medical Sciences, Fukuoka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000371DOI Listing
January 2015

Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.

Cancer Res 2014 Jun 27;74(11):3146-56. Epub 2014 Mar 27.

Authors' Affiliations: Massachusetts General Hospital Cancer Center, Charlestown; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Pathology, Massachusetts General Hospital, Boston, MassachusettsAuthors' Affiliations: Massachusetts General Hospital Cancer Center, Charlestown; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-3728DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046322PMC
June 2014

Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers.

Cancer Sci 2014 May 26;105(5):499-505. Epub 2014 Mar 26.

Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.12383DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317830PMC
May 2014

mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.

Cancer Discov 2014 Jan 25;4(1):42-52. Epub 2013 Oct 25.

1Massachusetts General Hospital Cancer Center; 2Department of Medicine, Harvard Medical School; 3Division of Gastroenterology, Department of Medicine, Tufts Medical Center; 4Department of Pathology, Massachusetts General Hospital, Boston; and 5Radiation Oncology, Steele Lab for Tumor Biology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0315DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973435PMC
January 2014

Apoptosis in targeted therapy responses: the role of BIM.

Adv Pharmacol 2012 ;65:519-42

Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-12-397927-8.00016-6DOI Listing
February 2013

Cyclins D3 and E go hand in hand with Cdk4/6 in diffuse large B-cell lymphoma.

Cell Cycle 2010 Feb 1;9(3):448-9. Epub 2010 Feb 1.

View Article

Download full-text PDF

Source
February 2010

Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas.

Cell Cycle 2007 Dec;6(23):2982-9

Department of Biology, Boston College, Chestnut Hill, Massachusetts 02467, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.6.23.4994DOI Listing
December 2007

Resveratrol induces apoptosis in transformed follicular lymphoma OCI-LY8 cells: evidence for a novel mechanism involving inhibition of BCL6 signaling.

Int J Oncol 2006 Dec;29(6):1561-6

Department of Biology, Boston College, Chestnut Hill, MA 02467, USA.

View Article

Download full-text PDF

Source
December 2006